Ascites
Conditions
Brief summary
A phase I, single-center, randomized, double-blind, placebo-controlled single dose escalation study, and a positive-controlled multiple dose extension study to evaluate the safety, tolerance, pharmacokinetics and immunogenicity of recombinant human albumin injection in healthy subjects
Detailed description
This study was to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of recombinant human albumin injection in healthy volunteers. The safety, tolerance, pharmacokinetics and immunogenicity of recombinant human albumin injection were evaluated in a single center, randomized, double-blind, placebo-controlled single dose incremental trial in healthy volunteers. The study was divided into two stages: the first stage was a single dose and dose increasing stage (including 5 dose groups with increasing dose, and each group was set with placebo control); the second stage was multiple administration stage (with positive control). The safety, tolerance, pharmacokinetics, immunogenicity and other early clinical data of recombinant human albumin were collected and analyzed in the two stages. The initial dose was 1.25g. The highest dose group was set at 30g. The dose groups of 1.25, 5, 10, 20 and 30 g / time were preset in the single dose stage (dose increasing stage). The dosage was 10 g / Day in multiple administration stage.
Interventions
single dose or multiple doses of intravenous infusion
DRUGPlacebo
Single dose intravenous infusion of 0.9% sodium chloride injection
DRUGhuman albumin injection
multiple doses of intravenous infusion
Sponsors
The First Hospital of Jilin University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
1）Informed consent form signed; 2) To be able to complete the study; 3) Subjects (including partners) are willing to take contraceptive measures; 4) 18-55 years of age; 5) Male subjects are no less than 50 kg.Female subjects are no less than 45 kg. Body mass index is 18-28kg / m2; 6) Normal cardiac function, defined as left ventricular ejection fraction (LVEF) ≥ 50%; 7) Physical examination and vital signs are normal.
Exclusion criteria
1. Cigarettes Smoking subjects. 2. Allergic constitution (multiple drugs and food allergies); 3. History of drug use and/or alcohol abuse; 4. Blood donation or massive blood loss (\> 450 mL) within three months before screening; 5. Taking any drugs, prescription, over-the-counter, vitamin products or herbal medicine within 14 days before screening; 6. Diet or exercise have changed recently; 7. Using study drugs within three months; 8. Risk of bleeding, such as hemorrhoids, acute gastritis or stomach and duodenal ulcers; 9. ECG abnormalities (QTc \> 470ms for males, \> 480ms for females); 10. Female subjects are in lactation. Pregnancy test is positive; 11. Other Clinical laboratory tests abnormalities; 12. Viral screening test is positive, including HBV, HCV, HIV, and Treponema pallidum; 13. Developing Acute disease; 14. Eating chocolate, any caffeine-containing or jaundice-rich food or drink 24 hours prior to the use of the study drug; 15. Taking any alcoholic products. Alcohol test is positive.. 16. Drug test is positive. History of drug abuse or drug use in the past five years; 17. Inability for intravenous injection or blood collection; 18. Using biological products (including live vaccines) within the last 3 months. Planing to use vaccines during the study period. Having received corticosteroid or human plasma product system treatment within 1 month. 19. Renal function is abnormal, glomerular filtration rate \<80 mL/min (according to the simplified MDRD formula); 20. History of glaucoma, eye disease. 21. History of cancer or other serious systemic diseases, especially heart, liver, kidney, digestive tract, nervous system, metabolic abnormalities, immune abnormalities or mental disorders; 22. History of immunodeficiency or hypofunction; 23. Received major surgery within 2 years. 24. Other subjects by investigator opinion..
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety and tolerance | Day 1-Day 57 for single doses study. Day 1-Day 106 for multiple doses study. | AE |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| PK parameters | Day 1-Day 57 for single doses study. Day 1-Day 106 for multiple doses study. | Maximum Plasma Concentration（Cmax） |
| Pharmacodynamic parameters | Day 1-Day 57 for single doses study. Day 1-Day 106 for multiple doses study. | Red blood cell specific volume |
| Immunogenicity | Day 1-Day 57 for single doses study. Day 1-Day 106 for multiple doses study. | Percentage of patients with positive reaction |
Countries
China
Outcome results
None listed